Methylnaltrexone for opioid-induced constipation in patients with advanced illness: A 3-month open-label treatment extension study

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 25, Issue 2, 2011, Pages 136-145

  Lipman, Arthur G ^a   Karver, Sloan ^b,c   Austin Cooney, Gail ^d   Stambler, Nancy ^e   Israel, Robert J ^e  

^a UNIVERSITY OF UTAH   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c Gulfside Regional Hospice   (United States)

^d Hospice of Palm Beach County   (United States)

^e Clinical Research   (United States)

Author keywords

advanced illness; clinical trial; extension trial; methylnaltrexone; opioid induced constipation

Indexed keywords

17 METHYLNALTREXONE; MORPHINE; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; AGITATION; ANXIETY; ARTICLE; BACKACHE; CANCER GROWTH; CONSTIPATION; CONTROLLED STUDY; DECUBITUS; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FEMALE; FLATULENCE; HUMAN; INTESTINE MOTILITY; LETHARGY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; PAIN; PAIN ASSESSMENT; PERIPHERAL EDEMA; SIDE EFFECT; SWEATING; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; WITHDRAWAL SYNDROME;

AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CONSTIPATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; QUATERNARY AMMONIUM COMPOUNDS; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 79958271806     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.3109/15360288.2011.573531     Document Type: Article

References (21)

1. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(5A Suppl):11S-18S. (Pubitemid 34072942)
2. Walsh T. Prevention of opioid side effects. J Pain Symptom Manage. 1990;5:362-367.
3. Walsh T. Oral morphine in chronic cancer pain. Pain. 1984;18:1-11 (Pubitemid 14219536)
4. Cameron. Constipation related to narcotic therapy. A protocol for nurses and patients. Cancer Nurs. 1992;15:372-377.
5. Sykes NP. The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med.1998;12: 375-382. (Pubitemid 28454405)
6. McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;4:231-256. (Pubitemid 36807905)
7. Schug SA, Zech D, Grond S. Adverse effects of systemic opioid analgesics. Drug Saf. 1992;7:200-213.
8. Bates JJ, Foss JF, Murphy DB. Are peripheral opioid antagonists the solution to opioid side effects? Anesth Analg. 2004;98:116-122. (Pubitemid 38029858)
9. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63:649-671. (Pubitemid 36408072)
10. Liu M, Wittbrodt E. Low-Dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage. 2002;23:48-53. (Pubitemid 34093880)
11. Paulson DM, Kennedy DT, Donovick RA, et al. Alvimopan: an oral, peripherally acting, [mu]-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction\a 21-day treatment-randomized clinical trial. J Pain. 2005;6: 184-192. (Pubitemid 40365022)
12. Yuan C-S, Wei G, Foss JF, O'Connor M, Karrison T, Osin-ski J. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Therap. 2002;300:118-123. (Pubitemid 34028517)
13. Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K. Oral naloxone reverses opioid-associated constipation. Pain. 2000;84:105-109.
14. Brown DR, Goldberg LI. The use of quaternary narcotic antagonists in opiate research. Neuropharmacology. 1985;24: 181-191. (Pubitemid 15051584)
15. Yuan C-S, Foss JF, O'Connor M, et al. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther. 2000;67:398-404. (Pubitemid 30246817)
16. Manara L, Bianchi G, Ferretti P, Tavani A. Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites. J Pharmacol Exp Therap. 1986;237:945-949 (Pubitemid 16088118)
17. Tavani. Morphine is most effective on gastrointestinal propulsion in rats by intraperitoneal route: evidence for local action. Life Sci. 1980;27:2211-2217.
18. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358:2332-2343. (Pubitemid 351749157)
19. Himmelsbach C. The morphine abstinence syndrome, its nature and treatment. Ann Intern Med. 1941;15:829-839.
20. Christakis NA, Lamont EB, Smith JL, Parkes CM. Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. BMJ. 2000;320:469-473.
21. De Schepper HU, Cremonini F, Park MI, Camilleri M. Opi-oids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil. 2004;16:383-394. (Pubitemid 39140632)